Leprosy Mailing List – April 7, 2023
Ref.: (LML) Telacebec
From: Paul Converse, Baltimore, USA
Dear Pieter,
The following reference which may have great significance eventually for the treatment of leprosy seems to have been omitted from the mailing list. I was able to share it with Wim van Brakel and Christian Johnson at the WHO meeting on neglected tropical skin diseases last week.
Our group at Johns Hopkins and other laboratories have done more extensive studies with M. ulcerans. The two organisms have a genetic defect that make them highly susceptible to the drug. It is not as potent in TB because M. tuberculosis has an intact gene. It has been shown to be safe in treating TB patients and healthy volunteers. If you would like these references, too, please let me know.
Thank you,
Paul Converse
Lahiri R, Adams LB, Thomas SS, Pethe K. Sensitivity of Mycobacterium leprae to Telacebec. Emerg Infect Dis. 2022 Mar;28(3):749-751. doi: 10.3201/eid2803.210394. PMID: 35202539; PMCID: PMC8888226.
LML - S Deepak, B Naafs, S Noto and P Schreuder
LML blog link: http://leprosymailinglist.blogspot.it/
Contact: Dr Pieter Schreuder << editorlml@gmail.com
--You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web visit https://groups.google.com/d/msgid/leprosymailinglist/bdf8b42d-f7fc-48f9-abf6-e79ab8cb2aeen%40googlegroups.com.
No comments:
Post a Comment